EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer

There is a need for predictive biomarkers that identify non-small-cell lung cancer (NSCLC) patients most likely to respond to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment. There are numerous potential candidates, although none has been proven in prospective clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Varella-Garcia, M, Diebold, J, Eberhard, D A, Geenen, K, Hirschmann, A, Kockx, M, Nagelmeier, I, Rüschoff, J, Schmitt, M, Arbogast, S, Cappuzzo, F
Formato: Texto
Lenguaje:English
Publicado: BMJ Group 2009
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2771853/
https://www.ncbi.nlm.nih.gov/pubmed/19861557
http://dx.doi.org/10.1136/jcp.2009.066548

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2771853/
https://www.ncbi.nlm.nih.gov/pubmed/19861557
http://dx.doi.org/10.1136/jcp.2009.066548

Ejemplares similares